Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Medtronic
Boehringer Ingelheim
Merck
McKinsey

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR IV PERSANTINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Iv Persantine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02273531 ↗ Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2004-01-01 Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Iv Persantine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed Southwest Oncology Group Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated United States Department of Defense Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated UConn Health Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00906035 ↗ The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) Terminated Boehringer Ingelheim N/A 2002-09-01 This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iv Persantine

Condition Name

Condition Name for Iv Persantine
Intervention Trials
Healthy 2
Coronary Artery Disease 2
Henoch-Schönlein Purpura Nephritis 1
HIV Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iv Persantine
Intervention Trials
Coronary Artery Disease 2
Myocardial Ischemia 2
Coronary Disease 2
Nephritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iv Persantine

Trials by Country

Trials by Country for Iv Persantine
Location Trials
United States 29
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iv Persantine
Location Trials
Pennsylvania 2
Connecticut 2
Massachusetts 1
Michigan 1
Mississippi 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iv Persantine

Clinical Trial Phase

Clinical Trial Phase for Iv Persantine
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iv Persantine
Clinical Trial Phase Trials
Completed 5
Terminated 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iv Persantine

Sponsor Name

Sponsor Name for Iv Persantine
Sponsor Trials
Boehringer Ingelheim 3
National Institute of Allergy and Infectious Diseases (NIAID) 1
Sharon Riddler 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iv Persantine
Sponsor Trials
Other 12
Industry 4
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
Dow
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.